文献速递儿童青少年精神心境障碍

成人注意缺陷多动障碍药物、心理及神经刺激干预的疗效与可接受性比较:系统综述与组分网络Meta分析

Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis.
PubMed 文献 · Lancet Psychiatry · 2025-01-01

该系统综述与组分网络Meta分析纳入113项随机对照试验共14887名成人注意缺陷多动障碍患者,比较药物、心理及神经刺激干预。短期核心症状改善方面,仅兴奋剂和阿托莫西汀在自评和他评量表上均优于安慰剂,但阿托莫西汀可接受性低于安慰剂。非药物干预仅在他评量表上优于安慰剂,且证据在不同评定者间不一致。

要点

  • 兴奋剂和阿托莫西汀在自评及他评量表上均显示短期改善注意缺陷多动障碍核心症状。
  • 阿托莫西汀和胍法辛的可接受性低于安慰剂,其余治疗组分与安慰剂相似。
  • 认知行为治疗、认知矫正、正念、心理教育及经颅直流电刺激仅在他评量表上优于安慰剂。

核心结论

  • 兴奋剂和阿托莫西汀是唯一在短期减少成人注意缺陷多动障碍核心症状方面有获益证据的干预,且自评和他评均支持。
  • 阿托莫西汀的可接受性低于安慰剂。
  • 注意缺陷多动障碍药物对生活质量等其他相关结局无效,长期证据研究不足。
  • 非药物策略的效应在不同评定者间不一致。

研究设计与样本

  • 系统综述与组分网络Meta分析,检索多个数据库从建库至2023年9月6日的已发表和未发表随机对照试验。
  • 纳入比较干预与对照或任何其他合格活性干预的随机对照试验,对象为年龄≥18岁且正式诊断注意缺陷多动障碍的成人。
  • 药物仅纳入最大计划剂量符合国际指南者;药物试验至少1周,心理治疗至少4次,神经刺激任何时长。
  • 药物、认知训练或神经刺激单独试验仅纳入双盲随机对照试验。
  • 共纳入113项独特随机对照试验,14887名参与者(女性6787名[45.6%],男性7638名[51.3%],性别未报告462名[3.1%])。

主要发现

  • 在12周时自评和他评量表上,阿托莫西汀(自评SMD -0.38,95%CI -0.56至-0.21;他评-0.51,-0.64至-0.37)和兴奋剂(自评-0.39,-0.52至-0.26;他评-0.61,-0.71至-0.51)的疗效高于安慰剂。
  • 认知行为治疗(-0.76,-1.26至-0.26)、认知矫正(-1.35,-2.42至-0.27)、正念(-0.79,-1.29至-0.29)、心理教育(-0.77,-1.35至-0.18)和经颅直流电刺激(-0.78,-1.13至-0.43)仅在他评量表上优于安慰剂。
  • 可接受性方面,阿托莫西汀(OR 1.43,95%CI 1.14至1.80)和胍法辛(OR 3.70,95%CI 1.22至11.19)的可接受性低于安慰剂,其余治疗组分与安慰剂相似。
  • 自评注意缺陷多动障碍核心症状基线严重度、发表年份、男性百分比及共病其他精神健康状况百分比未能解释非组分模型中观察到的异质性,治疗时长对异质性影响很小。

关键数值与推荐

  • 药物最大计划剂量须符合国际指南方可纳入。
  • 药物随机对照试验至少1周,心理治疗至少4次,神经刺激任何时长。
  • 药物、认知训练或神经刺激单独试验仅纳入双盲设计。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 注意缺陷多动障碍药物对生活质量等其他相关结局无效。
  • 长期证据研究不足。
  • 非药物策略的效应在不同评定者间不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The comparative benefits and harms of available interventions for ADHD in adults remain unclear. We aimed to address these important knowledge gaps. METHODS: In this systematic review and component network meta-analysis (NMA), we searched multiple databases for published and unpublished randomised controlled trials (RCTs) investigating pharmacological and non-pharmacological interventions for ADHD in adults from database inception to Sept 6, 2023. We included aggregate data from RCTs comparing interventions against controls or any other eligible active intervention for the treatment of symptoms in adults (ages ≥18 years) with a formal diagnosis of ADHD. Pharmacological therapies were included only if their maximum planned doses were considered eligible according to international guidelines. We included RCTs of at least 1-week duration for medications, of at least four sessions for psychological therapies, and of any length deemed appropriate for neurostimulation. For RCTs of medications, cognitive training, or neurostimulation alone, we included only double-blind RCTs. At least two authors independently screened the identified records and extracted data from eligible RCTs. Our primary outcomes were efficacy (change in ADHD core symptom severity on self-rated and clinician-rated scales at timepoints closest to 12 weeks) and acceptability (all-cause discontinuation). We estimated standardised mean differences (SMDs) and odds ratios (ORs) using random effects pairwise and component NMA, dismantling interventions into specific therapeutic components. This study was registered with PROSPERO (CRD42021265576). People with relevant lived experience were involved in the conduct of the research and writing process. FINDINGS: Of 32 416 records, 113 unique RCTs encompassing 14 887 participants were eligible for analysis (6787 [45·6%] females, 7638 [51·3%] males, 462 [3·1%] sex not reported). The RCTs encompassed pharmacological therapies (63 [55·8%] of 113 RCTs; 6875 participants), psychological therapies (28 [24·8%] of 113 RCTs; 1116 participants), neurostimulatory therapy and neurofeedback (ten [8·8%] of 113 RCTs; 194 participants), and control conditions (97 [85·8%] of 113 RCTs; 5770 participants). For reduction of ADHD core symptoms at 12 weeks on both self-reported and clinician-reported rating scales, atomoxetine (self-reported scale SMD -0·38, 95% CI -0·56 to -0·21; clinician-reported scale -0·51, -0·64 to -0·37) and stimulants (0·39, -0·52 to -0·26; -0·61, -0·71 to -0·51) had higher efficacy than placebo (Confidence in Network Meta-Analysis [CINeMA] ranging between very low and moderate). Cognitive behavioural therapy (-0·76, -1·26 to -0·26), cognitive remediation (-1·35, -2·42 to -0·27), mindfulness (-0·79, -1·29 to -0·29), psychoeducation (-0·77, -1·35 to -0·18), and transcranial direct current stimulation (-0·78; -1·13 to -0·43) were better than placebo only on clinician-reported measures. Regarding acceptability, all therapeutic components were similar to placebo other than atomoxetine (OR 1·43, 95% CI 1·14 to 1·80; CINeMA moderate) and guanfacine (3·70, 1·22 to 11·19; high), which had lower acceptability compared with placebo. Baseline severity of self-reported ADHD core symptoms, year of publication, percentage of male individuals, and percentage of individuals with ADHD and another mental health condition did not explain the heterogeneity observed in unadjusted non-component models of self-reported ADHD core symptoms. Treatment length had little effect on heterogeneity. INTERPRETATION: Stimulants and atomoxetine were the only interventions with evidence of beneficial effects in terms of reducing ADHD core symptoms in the short term, supported by both self-reported and clinician-reported ratings. However, atomoxetine was less acceptable than placebo. Medications for ADHD were not efficacious on additional relevant outcomes, such as quality of life, and evidence in the longer term is underinvestigated. The effects of non-pharmacological strategies were inconsistent across different raters. Our network meta-analysis represents the most comprehensive synthesis of available evidence to inform future guidelines in the field. FUNDING: UK National Institute for Health and Care Research.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Ostinelli EG, Schulze M, Zangani C, et al. Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. Lancet Psychiatry. 2025. PMID: 39701638. doi:10.1016/S2215-0366(24)00360-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。